Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor indicated for the treatment of adults with:1,2 Moderate to severe active rheumatoid arthritis (RA) Psoriatic arthritis Atopic dermatitis Ulcerative colitis Ankylosing spondylitis (AS) It is used for patients with RA for whom disease-modifying anti-rheumatic medicines (DMARDs) or methotrexate did not work well enough. It can be used on its own (monotherapy) or with methotrexate.1,2 It is available in extended-release tablet form each containing 15 mg of upadacitinib.1